Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Yasuhiro Osugi, Hitoshi Iwata, Yasushi Imai, Daiki Kobayashi, Ryutaro Hirashima
Cureus, doi:10.7759/cureus.21882
Aim: This study aimed to report clinical courses of patients who had mild coronavirus disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab/imdevimab in Japan, where mortality and number of severe patients were very limited compared to other resource-rich countries.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. The Ethical Committee of Toyota Regional Medical Center issued approval #2021-kenrin13. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Arentz, Yim, Klaff, Lokhandwala, Riedo et al., Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state, JAMA,
doi:10.1001/jama.2020.4326Gupta, Gonzalez-Rojas, Juarez, Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med,
doi:10.1056/NEJMoa2107934Liu, Fang, Deng, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province, Chin Med J (Engl),
doi:10.1097/CM9.0000000000000744Weinreich, Sivapalasingam, Norton, REGEN-COV antibody combination and outcomes in outpatients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2108163{ 'indexed': {'date-parts': [[2022, 2, 5]], 'date-time': '2022-02-05T03:14:52Z', 'timestamp': 1644030892122},
'reference-count': 11,
'publisher': 'Cureus, Inc.',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': [],
'published-print': {'date-parts': [[2022, 2, 3]]},
'DOI': '10.7759/cureus.21882',
'type': 'journal-article',
'created': {'date-parts': [[2022, 2, 3]], 'date-time': '2022-02-03T20:28:16Z', 'timestamp': 1643920096000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': ['Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan'],
'prefix': '10.7759',
'author': [ {'given': 'Yasuhiro', 'family': 'Osugi', 'sequence': 'first', 'affiliation': []},
{'given': 'Hitoshi', 'family': 'Iwata', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yasushi', 'family': 'Imai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Daiki', 'family': 'Kobayashi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ryutaro', 'family': 'Hirashima', 'sequence': 'additional', 'affiliation': []}],
'member': '4492',
'reference': [ { 'key': 'ref1',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2108163',
'article-title': 'REGEN-COV antibody combination and outcomes in outpatients with '
'COVID-19',
'volume': '385',
'author': 'Weinreich DM',
'year': '2021',
'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, et al.. REGEN-COV antibody '
'combination and outcomes in outpatients with COVID-19. N Engl J Med. '
'2021, 385:10.1056/NEJMoa2108163',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref2',
'unstructured': 'Japan becomes first country to approve Regeneron antibody cocktail '
'(casirivimab and imdevimab) for the treatment of mild to moderate '
'COVID-19. (2021). Accessed. January 16, 2022: '
'https://newsroom.regeneron.com/news-releases/news-release-details/japan-becomes-first-country-approve-regeneron-antib....'},
{ 'key': 'ref3',
'unstructured': 'WHO coronavirus (COVID-19) dashboard. (2022). Accessed. January 12, '
'2022: https://covid19.who.int/.'},
{ 'key': 'ref4',
'unstructured': 'Underlying medical conditions associated with higher risk for severe '
'COVID-19. information for healthcare providers. (2021). Accessed: '
'January 12, 2022: '
'https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.'},
{ 'key': 'ref5',
'doi-asserted-by': 'publisher',
'DOI': '10.1097/CM9.0000000000000744',
'article-title': 'Clinical characteristics of novel coronavirus cases in tertiary '
'hospitals in Hubei province',
'volume': '133',
'author': 'Liu K',
'year': '2020',
'unstructured': 'Liu K, Fang YY, Deng Y, et al.. Clinical characteristics of novel '
'coronavirus cases in tertiary hospitals in Hubei province. Chin Med J '
'(Engl). 2020, 133:1025-31. 10.1097/CM9.0000000000000744',
'journal-title': 'Chin Med J (Engl)'},
{ 'key': 'ref6',
'doi-asserted-by': 'crossref',
'unstructured': 'Severe outcomes among patients with coronavirus disease 2019 (COVID-19) '
'- United States, February 12-March 16, 2020. (2020). Accessed. January '
'16, 2022: https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm.',
'DOI': '10.15585/mmwr.mm6912e2'},
{ 'key': 'ref7',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2020.4326',
'article-title': 'Characteristics and outcomes of 21 critically Ill patients with '
'COVID-19 in Washington state',
'volume': '323',
'author': 'Arentz M',
'year': '2020',
'unstructured': 'Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. '
'Characteristics and outcomes of 21 critically Ill patients with COVID-19 '
'in Washington state. JAMA. 2020, 323:1612-4. 10.1001/jama.2020.4326',
'journal-title': 'JAMA'},
{ 'key': 'ref8',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2107934',
'article-title': 'Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody '
'sotrovimab',
'volume': '385',
'author': 'Gupta A',
'year': '2021',
'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al.. Early treatment for '
'COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. '
'2021, 385:1941-50. 10.1056/NEJMoa2107934',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref9',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2102685',
'article-title': 'Bamlanivimab plus etesevimab in mild or moderate COVID-19',
'volume': '385',
'author': 'Dougan M',
'year': '2021',
'unstructured': 'Dougan M, Nirula A, Azizad M, et al.. Bamlanivimab plus etesevimab in '
'mild or moderate COVID-19. N Engl J Med. 2021, 385:1382-92. '
'10.1056/NEJMoa2102685',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref10',
'unstructured': 'Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 '
'variant of concern (Omicron) for the EU/EEA. (2021). Accessed. January '
'16, 2022: '
'https://www.ecdc.europa.eu/sites/default/files/documents/Implications-emergence-spread-SARS-CoV-2%20B.1.1.529-variant....'},
{ 'key': 'ref11',
'unstructured': 'Enhancing response to Omicron SARS-CoV-2 variant. (2022). Accessed. '
'January 16, 2022: '
'https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-acti....'}],
'container-title': ['Cureus'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.cureus.com/articles/83767-clinical-prognosis-of-patients-with-mild-covid-19-treated-with-casirivimabimdevimab-in-japan',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 2, 3]],
'date-time': '2022-02-03T20:28:20Z',
'timestamp': 1643920100000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 2, 3]]},
'references-count': 11,
'URL': 'http://dx.doi.org/10.7759/cureus.21882',
'relation': {},
'ISSN': ['2168-8184'],
'issn-type': [{'value': '2168-8184', 'type': 'print'}],
'subject': ['Aerospace Engineering'],
'published': {'date-parts': [[2022, 2, 3]]}}
